Professional Documents
Culture Documents
Research Article
Cervical cancer is among the most commonly diagnosed cancers in women worldwide. it may
persist or recur months or years after completion of the primary treatment. Management of the
residual /recurrent disease depends on mode of primary treatment and the extent of recurrence.
The treatment options for these include chemotherapy, radiotherapy or surgery. The role of
chemotherapy in cervical cancer recurrence is palliative only. This was a prospective study
conducted in Dr.B.Borooah Cancer Institute, Guwahati, Assam, A grant in aid institute of
Department of Atomic Energy, Govt.of India from October 2017 to March 2019. In our study we
evaluated the clinical outcome of oral Gefitinib in recurrent carcinoma cervix cases. The main
objective was to investigate the correlation of baseline EGFR expression with tumor response
and disease control with Gefitinib. 30 patients with recurrent carcinoma cervix were treated with
Gefitinib. Out of these 10 patients had progression of disease during the study period. Median
PFS was 10 months. Overall progression free survival and median overall survival was 42.6% and
93.3% respectively at the end of study period of 18 months. Gefitinib is a good option as oral
chemotherapy having a good PFS with minimal side effects for recurrent carcinoma of cervix in
palliative setting.
Keywords: cervical cancer, chemotherapy, radiotherapy, EGFR (epidermal growth factor receptor), Gefitinib, PFS
(progression free survival).
INTRODUCTION
Cervical cancer is among the most commonly diagnosed al1990). A 10-20% recurrence rate has been reported
cancers in women worldwide. In 2018, according to the following primary surgery or radiotherapy in patient with
GLOBOCAN estimates, there were 5,69,847 new cases of stage 1b-2a cervical cancers without lymph node
cervical cancer worldwide and in India cervical cancer is involvement. The rate increases upto70% in patients with
the third most common cancer with 96922 new cases nodal metastasis and/or locally advanced disease
(Bray et a l2018,Ferlay j et al 2018).cervical cancer may (Burgghardt et al1992, Perez et al1995,Stehman FB et al
have high mortality(Turkiye klinikleri 2018) .It ranked 4th as 1991,Ziano r j et al1992).
far as mortality is concerned with 60078 death (Bray et al
2018,Ferlay j et al 2018).
*Corresponding Author: Bipul Prasad Deka, U Fellow,
Cervical cancer may persist or recur months or years after Department of Gynae-oncology Dr. B. Borooah Cancer
the completion of initial cancer directed treatment, which Institute, Guwahati, Assam. E-mail:
may have included surgery, radiation and/or bipuldeka012@gmail.com, Tel: 7002692997.
chemotherapy. The recurrence may be local/pelvic, distant Co-Author Email: 1drdbarmon@gmail.com;
3
metastases, or a combination of both. The recurrence rate dramalchkataki@yahoo.com; 4drdimpyb@gmail.com;
5
is lower for those with early stage disease (Delgado et megha.nandwani@gmail.com
To determine the progression free survival, overall survival HB% 9 gm/dl. WBC>3000/cubic mm, Absolute
and toxicity following use of Gefitinib. granulocyte count >1500/cubic mm, Platelet count
>100000/microlt.
Role of Oral Gefitinib In Recurrent Carcinoma Cervix in Relation to EGFR Status
J. Cancer Clin. Oncol. 026
Table 3:Status at the end of study: palliative. Targeted therapeutics represents a promising
Status area which needs further research( Motte Rouge
2006).There are limited data or publications regarding the
Valid Cumulative efficacy of Gefitinib in recurrent cervical cancer cases.
Frequency Percent Percent Percent
80% of lung cancer patients who are carriers of EGFR tk
Valid Alive 28 93.3 93.3 93.3 domain mutations experience partial response or marked
Dead 2 6.7 6.7 100.0 clinical improvement with Gefitinib or Elrotinib. Patients
without such mutations are refractory to these agents(
Total 30 100.0 100.0 Lynch TJ 2004)
Out of 30 patients 28 patients were alive at the end of the
study. In our study majority cases were found to be squamous
cell carcinoma .EGFR expressed in about 88% cases of
Table 4:Response to treatment at 18 months squamous cell carcinoma and about 75% cases of
Total patients for study 30 adenocarcinoma. A median progression free survival of 10
Alive 28 months was observed.Overall progression free survival
Complete remission Nil and median overall survival was 42.6% and 93.3%
Partial remission Nil respectively at the end of study period. Disease response
Progressive disease 10 in relation to EGFR status could not be evaluated as EGFR
Stable disease 20 negative sample is too low (only 4 cases were EGFR
negative).These findings can be compared with following
Expired 02
studies.
Patient leaving study duo to toxicity Nil
Progression free survival 10 months
A Goncalves et al(2008) in their study evaluated 28
Median overall survival 93.3% patients for efficacy of Gefitinib in recurrent ca cervix. In
WHO status their study no objective response was found.6 patients had
0 stable disease lasting 77 -118 days(median 111.5
1 5 days).22 patients had progressive disease. Median time to
2 11 progression was 37 days. Median overall survival was 107
3 12 days. At closure of trial 10% patients were alive. In their
study 86.7% of the cases expressed EGFR positivity .No
Adverse effects correlation was found between EGFR expression and
disease control.
In our study 12 patients had anaemia of varying degree.
Out of these 7 patients had on and off bleeding per vagina, In our study 81% patients showed EGFR positivity.
so anaemia may not be related to the drug. 10 patients had Sharma, Dayanand et al(2013) evaluated 20 recurrent ca
symptom of anorexia. Acne like rash appeared in 2 cervix cases with Gefitinib. The median PFS was 4
patients which was treated with soothing agent. 3 patients months. Median OS was 5 months. Toxicity of Gefitinib
gave history of excessive discharge per vagina. 1 patient was within acceptable limit.
had diarrhoea after starting the drug, treated with iv fluids.
Russell j et al(2009) in their phase 2 trial of Elrotinib in
recurrent squamous cell carcinoma cervix evaluated 25
DISCUSSION patients. In their study no objective response was
found.16% patients had stable disease.1 patient had PFS
Current treatment for advanced stage/recurrent cervical of > 6months.
carcinoma has only limited efficacy and is most often
Pao W,Miller V,Zakowski m et al( September 2004)”EGFR Thigpen T, Shingleton H, Homesley H et al. Cisplatin in the
receptor gene mutations are common in lung cancers treatment of advanced or recurrent squamous cell
from never smokers and are associated with sensitivity carcinoma of cervix: a phase II study of the Gynecologic
of the tumours to gefitinib and erlotinib. Proceedings of Oncology Group. Cancer. 48:899-903. 1981. View
the national academy of sciences of the united states article : Google Scholar : PubMed/NCBI.
of America.101(36) :13306-11. Tiersten A.D., Selleck M.J., Hershman D.L., et al: Phase II
Perez CA, Grigsby PW, Camel HM et al. Irradiation alone study of topotecan and paclitaxelfor recurrent,
or combined with surgery in stage IB, IIA and IIB persistent, or metastatic cervical carcinoma. Gynecol
carcinoma of the uterine cervix: update of a Oncol 2004; 92: pp. 635-638Cross Ref
nonrandomized comparison. Int J Radiat Oncol Biol (http://dx.doi.org/10.1016/j.ygyno.2003.11.019)
Phys 1995;31:703-716. Turkiye klinikleri j Gen Surg-Special topics
Rose P.G., Blessing J.A., Gershenson D.M., and 2018,11(2):112-4
McGehee R.: Paclitaxel and cisplatin as first- Ziano RJ, Ward S, Delgado E et al. Histopathological
linetherapy in recurrent or advanced squamous cell predictors of the behaviour of surgically treated stage
carcinoma of the cervix: a Gynecologic Oncology IB squamosous cell carcinoma of the cervix. A
Group study. J Clin Oncol 1999; 17: pp. 2676- Gynecologic Oncology Group study. Cancer
2680Cross Ref (http://dx.doi.org/10.1200/JCO. 1992;69:1750-1758.
1999.17.9. 2676)
Rossi s, editor. australians medicine handbook;2004.ISBN
0-9578521-4-2. CONFLICT OF INTEREST
Scambia G, Ferrandina G, Distefano M,et al Epidermal
growth factor receptor ( EGFR) is not related to the There is no conflict of interest amongst the authors.
prognosis of cervical cancer.cancer let.1998;123:135-9
(pubmed).
Schilder Russell J, Sill Michael W, Lee,Yi-Chun,
Mannel Robert. A phase ii trial of erlotinib in recurrent
squamous cell carcinoma of the cervix: a gynecologic
oncology group studyInt J Gynecol Cancer. 2009 Jul;
19(5): 929–933
Sharma DN, Rath GK, Julka PK, Gandhi AK, Jagadesan
P, Kumar S. Role of gefitinib in patients with recurrent
or metastatic cervical carcinoma ineligible or refractory
to systemic chemotherapy: first study from Asia. Int J Accepted 10 June 2019
Gynecol Cancer. 2013;23: 705–709.pmid:23466569
Sordella r, bell dw,haber DA,settlemen j (august 2004) Citation: Barmon D, Deka BP, Kataki AC, Begum D,
“gefitinib sensitizing EGFR mutations in lung cancer Nandwani M (2019). Role of Oral Gefitinib In Recurrent
activate anti apoptotic pathways” science 305 Carcinoma Cervix in Relation to EGFR Status. Journal of
(5687):11637. Cancer and Clinical Oncology 3(2): 024-029.
Stehman FB, Bundy BN, Disaia PJ et al. Carcinoma of the
cervix treated with radiation therapy. I. A multivariate
analysis of prognostic variables in the Gynecologic
Oncology Group. Cancer 1991;67:2776-2785.
Taba T,Barmon D, Begum D et al. management of Copyright: © 2019: Barmon et al. This is an open-access
recurrent or residual cervical cancer with cisplatin and article distributed under the terms of the Creative
topotecan combination therapy in a palliative setting; A Commons Attribution License, which permits unrestricted
Prospective study. Indian journal of gynaecologic use, distribution, and reproduction in any medium,
oncology vol 16. 10.1007/s40944-018-0239-0 provided the original author and source are cited.